This new project seeks to extend the work on neuropsychological assessment accomplished in the Program's initial period of funding. Its objective is to extend the current method of quantitative performance evaluation of ADC, focussing on more sensitive measures that might prove valuable in multidisciplinary studies directed at the underlying pathophysiological mechanism of ADC. Starting with a well-standardized procedure, this project will establish the utility of a Continuous Performance Task (CPT), using a reaction time measure of sustained attention to characterize ADC. The utility of CPT as a sensitive, early measure of treatment effects in studies of anti-retroviral therapy and of therapies directed at potential neuropathophysiological mechanisms of ADC will also be studied. As a correlate of the CPT measure, its corresponding event related potential (ERP) will also be studied with respect to ADC. Both the CPT and event related potential measures will be studied during FDG/PET scanning in collaboration with Project 4. The objective of these studies is not to replace the previously established methods of the neuropsychological assessment of ADC, but to develop more sensitive measures of impairment in this syndrome that can play a significant role in studying treatment effects and potential pathophysiological mechanisms. In the context of this Program, these studies will be integrated with the studies of regional cerebral metabolism, quantitative MRI, and EEG power spectra, and will play an important role in correlative studies using surrogate markers of direct and indirect effects of HIV-1 infection of the CNS.

Project Start
1997-02-01
Project End
1999-01-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Price, R W; Yiannoutsos, C T; Clifford, D B et al. (1999) Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 13:1677-85
Rehm, K; Lakshminaryan, K; Frutiger, S et al. (1998) A symbolic environment for visualizing activated foci in functional neuroimaging datasets. Med Image Anal 2:215-26
Liow, J S; Strother, S C; Rehm, K et al. (1997) Improved resolution for PET volume imaging through three-dimensional iterative reconstruction. J Nucl Med 38:1623-31
Sidtis, J J; Dafni, U; Slasor, P et al. (1997) Stable neurological function in subjects treated with 2'3'-dideoxyinosine. J Neurovirol 3:233-40
Price, R W (1996) AIDS dementia complex: a complex, slow virus ""model"" of acquired genetic neurodegenerative disease. Cold Spring Harb Symp Quant Biol 61:759-70
Rottenberg, D A; Sidtis, J J; Strother, S C et al. (1996) Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 37:1133-41
Wang, G J; Thayer, S A (1996) Sequestration of glutamate-induced Ca2+ loads by mitochondria in cultured rat hippocampal neurons. J Neurophysiol 76:1611-21
Price, R W (1996) The cellular basis of central nervous system HIV-1 infection and the AIDS dementia complex: introduction. J NeuroAIDS 1:1-29
Price, R W (1996) Neurological complications of HIV infection. Lancet 348:445-52
Price, R W (1995) Management of AIDS dementia complex and HIV-1 infection of the nervous system. AIDS 9 Suppl A:S221-36

Showing the most recent 10 out of 45 publications